Shameless Green Day Appreciation Thread, page-24

with the hype and hope of ADAPT and the HSV work, from memory, the SP reached $0.18 ($180 post 1000:1 consolidation).
so the share holders have pushed the price that high before. history may repeat although it is now a very different company.

if things progress as we all hope, AVR becomes a real competitor in the TAVR space and take some (a little, or a lot) of the multi billion $ market space........

the financials if AVR gains traction with the clinicians and sales/revinue/market share increase can suggest a number of 'what if' calculations..which correct me if I am wrong..but $200 and even $300/ share have been 'suggested'.....

HOwever, Edwards and Medtronics (main competitors in this space) SP is about $90 to 100 USD......will the public or investors be prepared to pay more than that for AVR??????

I hope they will...... maybe somone with better skills than I can propose some what if scenarios to project revenue/profit/SP based on number of procedures using the product when commercialised to answer your question with more accuracy.